TICKERNERD
Menu
ACONACONHealthcare · Health Information Services

ACON Stock Forecast: Aclarion, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$2.66
−1.85% on the day

The 1 Wall Street analysts covering Aclarion, Inc. hold a median 12-month price target of $7.5 — +182.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$7.8M
Ticker Nerd rank
33 / 100
Median analyst target
$7.50
Analysts covering
1
Revenue$25K+30.5% y/y
Operating income−$2.9M
Net income−$2.7M
Free cash flow−$2.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.0%
1M
+9.9%
YTD
−42.2%
1Y
−63.6%
From 52W high
−72.5%
From 52W low
+32.0%
$2.02
$9.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ACON stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aclarion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Revisions
58
Accruals
57
Growth
53
Volatility
45
Quality
39
Momentum
28
Issuance
23
Value
1

Size (94): Smaller than most of the companies we track.

Value (1): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ACON stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ACON, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26ACONHigh $7.50Median $7.50Low $7.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $7.50Median $7.50High $7.50

The green dot is the last close — the median target sits +182.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
29 May 2026Ascendiant CapitalMaintainsBuy$7.00 → $7.50
25 Mar 2026Ascendiant CapitalMaintainsBuy—
20 Nov 2025Ascendiant CapitalMaintainsBuy—
19 Sept 2025Ascendiant CapitalMaintainsBuy—
13 Dec 2024Maxim GroupDowngradeHold—
27 Nov 2024Ascendiant CapitalMaintainsBuy—
26 Aug 2024Ascendiant CapitalMaintainsBuy—
29 July 2024Ascendiant CapitalInitiatesBuy—
6 July 2022Maxim GroupInitiatesBuy$3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ACON appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ACON vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Aclarion, Inc. returned −63.6% against +19.6% for the S&P 500, dividends included.

ACON vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26ACONS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ACON analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Aclarion, Inc. (ACON) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.2×

Cheaper than 78% of US stocks

Price / sales
93.2×

Cheaper than 4% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
0.9×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
30.5%

Higher than 79% of US stocks

Earnings growth (YoY)
30.5%

Higher than 66% of US stocks

Gross margin
32.9%

Higher than 39% of US stocks

Operating margin
−11503.2%

Higher than 2% of US stocks

Net margin
9.0%

Higher than 68% of US stocks

Returns & dividend
Return on equity
−59.0%

Higher than 19% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
146.5%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Aclarion, Inc. (ACON) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Aclarion, Inc. has a market value of $7.8M and an enterprise value of −$8.5M.

  • Revenue in the twelve months to 30 June 2026: $84K. The latest quarter grew 30.5% year on year.

  • Net income over the same four quarters: −$9.2M, a −10978.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$8.3M.

  • Aclarion, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 2.4M.

  • Trailing P/E: −0.2×; forward P/E: −0.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 146.52%, paying out 0% of earnings.

  • Aclarion, Inc. employs 10 people — $8K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 23 Aug 2026

Data provided by Twelve Data

Peers

ACON vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
ACONAclarion, Inc.$7.8M
33
MGRXMangoceuticals, Inc.$9.1M
44
BFRGBullFrog AI Holdings, Inc.$10.8M
37
HCTIHealthcare Triangle, Inc.$13.2M
22
VSEEVSee Health, Inc.$2.8M
—
BEATHeartBeam, Inc.$27.8M
18
MNDRMobile-health Network Solutions$2.0M
13

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aclarion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ACON news & analysis

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

GlobeNewsWire · 20 Aug 2026positive

Aclarion announced that the University of Arizona College of Medicine - Phoenix has been added as a clinical site in its CLARITY trial, a prospective, randomized study evaluating Nociscan's ability to improve surgical outcomes for chronic low back pain. The addition brings the trial to ten actively enrolling sites.

Why it matters — A new enrolling site expands the footprint of Aclarion's key CLARITY trial, advancing progress toward validating Nociscan for identifying sources of low back pain.

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

GlobeNewsWire · 12 Aug 2026positive

Aclarion announced that the USPTO issued a Notice of Allowance for a patent application titled "Multi-Voxel Prescription for Lumbar Disc Evaluation," which protects the precision of MRS data capture within the target disc as part of the Nociscan workflow. The patent is designed to reduce scan time, support faster technologist onboarding, and deliver more reproducible results, extending Aclarion's IP protection to over 65 issued and pending patents worldwide.

Why it matters — ACON watchers would care because this patent allowance bolsters Aclarion's intellectual property protection around its Nociscan MRS process, potentially supporting the accuracy and broader adoption of its technology across imaging centers.

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 6 Aug 2026negative

Aclarion, Inc. reported a Q2 loss of $1.12 per share, wider than the Zacks Consensus Estimate of a $1.05 loss, but narrower than the year-ago loss of $2.75 per share. The headline indicates the company lagged revenue estimates.

Why it matters — Aclarion watchers would track this report because the quarterly loss missed analyst estimates, signaling weaker-than-expected performance despite improvement from the prior year.

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

GlobeNewsWire · 4 Aug 2026positive

Aclarion announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, making it the first site in Indiana to offer the technology. The company said the availability reflects its focus on expanding its base of provider sites across the country.

Why it matters — The announcement marks continued expansion of Nociscan into a new state and adds another provider site to Aclarion's growing base, which is central to investors tracking the commercial rollout of the technology.

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

GlobeNewsWire · 29 July 2026positive

Aclarion published a shareholder letter from CEO Brent Ness updating shareholders on the company's progress in the first half of 2026, citing 141% year-over-year scan volume growth, a newly launched U.S. Market Access Program with PRIA Healthcare, and a strengthened IP portfolio with 65 patents.

Why it matters — ACON watchers would care because the letter provides a direct update from management on operational milestones including scan volume growth, U.S. reimbursement efforts, and trial progress.

FAQ

Frequently asked questions about ACON stock

What is the ACON stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Aclarion, Inc. have a median 12-month price target of $7.5, with estimates ranging from $7.5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ACON stock a buy right now?

Of the 1 analysts covering Aclarion, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aclarion, Inc. 33 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ACON?

As at 22 Aug 2026, Aclarion, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will ACON stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +182.0% from the last close, and Ticker Nerd's factor model ranks Aclarion, Inc. 33 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ACON stock forecast for 2030?

No analyst covering Aclarion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACON are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7.5 to $7.5 over the next 12 months.

How has ACON stock performed over the past year?

Aclarion, Inc. returned -63.6% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aclarion, Inc. do?

Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain.

What is the latest news on ACON?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site". Aclarion announced that the University of Arizona College of Medicine - Phoenix has been added as a clinical site in its CLARITY trial, a prospective, randomized study evaluating Nociscan's ability to improve surgical outcomes for chronic low back pain. The addition brings the trial to ten actively enrolling sites.

Company

About Aclarion, Inc.

Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain. The company combines magnetic resonance spectroscopy (MRS) imaging with proprietary augmented-intelligence algorithms to create software-as-a-service (SaaS) solutions that help physicians personalize treatment plans and optimize clinical outcomes. The company's primary offering is the NOCISCAN Suite, which uses MRS capabilities to noninvasively analyze the chemical composition of intervertebral discs in the spine. Aclarion's suite includes the NOCISCAN MRS Exam Protocol for standard lumbar MRI exams, the NOCISCAN Post-Processor Suite with NOCICALC and NOCIGRAM applications that process spectroscopy data and calculate degenerative pain biomarkers, and complementary imaging data transfer platforms. By leveraging artificial intelligence to assist in quality control processes and proprietary biomarkers, Aclarion aims to address unmet clinical needs in musculoskeletal pain management and help patients achieve improved health outcomes and pain relief.

CEO Mr. Brent Ness · 10 employees · United States · https://www.aclarion.com